Researchers from the cancer nanotechnology and signal transduction and therapeutics programs of UCLA’s Jonsson Comprehensive Cancer Center (JCCC) have developed an innovative technique using light to carry chemotherapy safely to cancer cells.
Drs. Jeffrey Zink, professor of chemistry and biochemistry, and Fuyu Tamanoi, professor of microbiology, immunology and molecular genetics, and colleagues published their findings in the journal Small on February 20, 2014.
A light-activated drug delivery system is particularly promising, because it can accomplish spatial and temporal control of drug release. Finding ways to deliver and release anticancer drugs in a controlled manner that only hits the tumor can greatly reduce the amount of side effects from treatment, and also greatly increase the cancer-killing efficacy of the drugs. The difficulty of treating cancer often derives from the challenges of getting anticancer chemotherapy drugs to tumor cells without damaging healthy tissue in the process. Many cancer patients experience treatment side effects that are the result of drug exposure to healthy tissues.
A major challenge in the development of light-activated drug delivery is to design a system that can respond to tissue-penetrating light. Drs. Tamanoi and Zink joined their diverse teams and collaborated with Dr. Jean-Olivier Durand at University of Montpellier, France to develop a new type of microscopic particles (nanoparticles) that can absorb energy from tissue-penetrating light that releases drugs in cancer cells.
These new nanoparticles are equipped with specially designed nanovalves that can control release of anticancer drugs from thousands of pores, or tiny tubes, which hold molecules of chemotherapy drugs within them. The ends of the pores are blocked with capping molecules that hold the drug in like a cork in a bottle. The nanovalves contain special molecules that respond to the energy from two-photon light exposure, which opens the pores and releases the anticancer drugs. The operation of the nanoparticles was demonstrated in the laboratory using human breast cancer cells.
Because the effective depth range of the two-photon laser in the infrared red wavelength can reach four centimeters from the skin surface, this delivery system is best for tumors that can be reached within that range, which possibly include breast, stomach, colon, and ovarian cancers.
Another feature of the nanoparticles is that they are fluorescent and thus can be tracked in the body with molecular imaging techniques. This allows the researchers to track the progress of the nanoparticle into the cancer cell to insure that it is in its target before light activation. This ability to track a targeted therapy to its target has been given the name “theranostics” (a portmanteau of therapy and diagnostics) in the scientific literature.
“We have a wonderful collaboration,” said Zink. “When the JCCC brings together totally diverse fields, in this case a physical chemist and a cell signaling scientist, we can do things that neither one could do alone.”
“Our collaboration with scientists at Charles Gerhardt Institute was important to the success of this two-photon activated technique,” said Tamanoi. “It provides controls over drug delivery to allow local treatment that dramatically reduces side effects.”
The Latest on: Light-activated drug delivery system
[google_news title=”” keyword=”Light-activated drug delivery system” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Light-activated drug delivery system
- Drug Delivery Technologies market is projected to grow at a CAGR of 5.5% by 2034: Visiongainon April 26, 2024 at 6:15 am
Visiongain has published a new report entitled Drug Delivery Technologies Market Report 2024-2034: Forecasts by Route of Administration (Implantable Drug Delivery, Injectable Drug Delivery Nasal Drug ...
- Randomised controlled trials evaluating artificial intelligence in clinical practice: a scoping reviewon April 24, 2024 at 5:39 pm
This scoping review of randomised controlled trials on artificial intelligence (AI) in clinical practice reveals an expanding interest in AI across clinical specialties and locations. The USA and ...
- A nanophotonic fiber-tip solution to detect the ultrasmallon April 24, 2024 at 5:00 pm
To overcome these issues, our researchers have designed a new ultra-sensitive fiber-tip sensor that can detect ... such as cancer. And in drug development, a host of nanoparticles are used to make the ...
- A closed-loop drug-delivery system could improve chemotherapyon April 24, 2024 at 1:54 pm
To improve chemotherapy dosing, MIT engineers designed CLAUDIA, a way to continuously measure how much drug is in a patient’s system during hours-long infusion.
- Ultrasensitive photonic crystal detects single particles down to 50 nanometerson April 24, 2024 at 12:49 pm
Using an ultrasensitive photonic crystal, TU/e researchers were able to detect single particles down to 50 nanometers in diameter. The new research has just been published in the journal Optica.
- Sanofi gets grant for optical decoding system for determining medicament dose in drug delivery deviceon April 24, 2024 at 6:18 am
Enhance medication dosing accuracy with Sanofi's patented optical decoding system for drug delivery devices. Improve efficiency and precision in dispensing with this innovative technology.
- Nanotechnology Market worth $189.39 billion by 2028, at a CAGR of 14.10% - IndustryARCon April 17, 2024 at 5:05 pm
According to the latest Market research report on the Nanotechnology Market, published by IndustryARC, the Nanotools segment is estimated to experience the fastest CAGR of 18.63% during the forecast ...
- An effective drug delivery system for next-generation treatments to hitch a ride in cancer cellson April 16, 2024 at 9:22 am
Antisense oligonucleotides (ASOs) are next-generation drugs that can treat disease by blocking the transfer of harmful messages from our genes. In people with cancer, ASOs have the potential to block ...
- ERC Advanced Grant: Andreas Herrmann receives 2.5 million euros from the EUon April 15, 2024 at 11:38 pm
Professor Andreas Herrmann is developing a new technology platform for controlling the activity of genes, proteins and active pharmaceutical ingredients using biocompatible ultrasound. He has been ...
- $5+ Billion 3D Mapping Modelling Markets - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2022 and 2023-2028on April 15, 2024 at 8:12 am
Overall, the 3D Mapping and Modeling market reflects a transformative force, shaping how industries visualize, understand, and interact with the physical world through innovative spatial data ...
via Bing News